Morphomer-NLRP3-ASC (AC Immune)

N/A

Report date: 2025/01/26 17:12:08
NME

Base Information

Drug NameMorphomer-NLRP3-ASC (AC Immune)
Drug Alias NameNLRP3-ASC Inflammasome Targeting Therapy (AC Immune)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitorsApoptosis-associated speck-like protein containing a CARD inhibitors
TargetsApoptosis-associated speck-like protein containing a CARDNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAc Immune Sa
China Registration ClassN/A

Develop Information

Active CompaniesAc Immune Sa
Inactive CompaniesN/A
Active IndicationsNerve Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A